Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
Abstract Background Prostate cancer is a heterogeneous disease, meaning patients would benefit from different treatment strategies based on their molecular stratification. In recent years, several genomic studies have identified prostate cancers with defects in DNA repair genes. It is known that the...
Saved in:
Main Authors: | Yi Ma (Author), Lijie He (Author), Qianwen Huang (Author), Shuang Zheng (Author), Zhiqiang Zhang (Author), Hongshi Li (Author), Shuang Liu (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2018-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021) -
Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
by: Dan Su, et al.
Published: (2021) -
Promising Response of Olaparib in Patient With Germline -Mutated Metastatic Gastric Cancer
by: Kok Hoe Chan MD, et al.
Published: (2024) -
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015) -
Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019)